Zenas BioPharma, Inc. (ZBIO) annual income statement — 4-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 10M | 5M | 50M | 0 |
| Revenue Growth % | -100% | 100% | -90% | - | - |
| Cost of Goods Sold | 48.03M | 0 | 139.14M | 0 | 61.69M |
| COGS % of Revenue | - | - | 2782.78% | - | - |
| Gross Profit | -48.03M | 10M | -134.14M | 50M | -61.69M |
| Gross Margin % | - | 100% | -2682.78% | 100% | - |
| Gross Profit Growth % | - | 107.45% | -368.28% | 181.05% | - |
| Operating Expenses | 375.04M | 221.38M | 29.75M | 87.15M | 14.51M |
| OpEx % of Revenue | - | 2213.85% | 594.98% | 174.29% | - |
| Selling, General & Admin | 57.81M | 53.32M | 29.75M | 17.11M | 13.51M |
| SG&A % of Revenue | - | 533.22% | 594.98% | 34.23% | - |
| Research & Development | 193.59M | 168.06M | 139.14M | 60.03M | 62.69M |
| R&D % of Revenue | - | 1680.63% | 2782.78% | 120.07% | - |
| Other Operating Expenses | 0 | 0 | -139.14M | 10M | -61.69M |
| Operating Income | -423.08M | -211.38M | -163.89M | -37.15M | -76.2M |
| Operating Margin % | - | -2113.85% | -3277.76% | -74.29% | - |
| Operating Income Growth % | - | -28.98% | -341.19% | 51.25% | - |
| EBITDA | -423.04M | -211.33M | -163.75M | -37.03M | -76.12M |
| EBITDA Margin % | - | -2113.29% | -3275.02% | -74.07% | - |
| EBITDA Growth % | -143.81% | -29.06% | -342.16% | 51.35% | - |
| D&A (Non-Cash Add-back) | 39K | 56K | 137K | 113K | 78K |
| EBIT | -414.43M | -370.49M | -163.89M | -27.15M | -75.2M |
| Net Interest Income | -3.61M | 4.82M | 0 | 0 | 0 |
| Interest Income | 3.02M | 12.15M | 0 | 0 | 0 |
| Interest Expense | 6.63M | 7.33M | 0 | 0 | 0 |
| Other Income/Expense | -1.95M | -166.43M | 7.33M | 324K | -43.08M |
| Pretax Income | -425.02M | -377.82M | -156.56M | -36.82M | -119.28M |
| Pretax Margin % | - | -3778.16% | -3131.18% | -73.65% | - |
| Income Tax | 126K | -79K | 429K | 301K | 0 |
| Effective Tax Rate % | -0.03% | 0.02% | -0.27% | -0.82% | 0% |
| Net Income | -425.15M | -377.74M | -156.99M | -37.12M | -119.28M |
| Net Margin % | - | -3777.37% | -3139.76% | -74.25% | - |
| Net Income Growth % | -161.21% | -140.62% | -322.87% | 68.88% | - |
| Net Income (Continuing) | -425.15M | -377.74M | -156.99M | -37.12M | -119.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.64 | -8.44 | -3.76 | -0.97 | -3.11 |
| EPS Growth % | -129.22% | -124.47% | -287.63% | 68.81% | - |
| EPS (Basic) | - | -8.44 | -3.76 | -0.97 | -3.11 |
| Diluted Shares Outstanding | 55.62M | 44.73M | 41.79M | 38.32M | 38.32M |
| Basic Shares Outstanding | 55.62M | 44.73M | 41.79M | 38.32M | 38.32M |
| Dividend Payout Ratio | - | - | - | - | - |
Quick answers to the most common questions about buying ZBIO stock.
For fiscal year 2025, Zenas BioPharma, Inc. (ZBIO) reported total revenue of $10.0M.
Zenas BioPharma, Inc. (ZBIO) reported a net loss of $377.7M for the fiscal year ending 2025.
Zenas BioPharma, Inc. (ZBIO) reported an operating income of $-211.4M, resulting in an operating profit margin of -2113.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Zenas BioPharma, Inc. (ZBIO) generated $10.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.